Considering the tumor-infiltrating T cell clonal replacement that occurs after anti–PD-1 therapy (79), treatment with ICB is expected to induce the expansion of specific T cell populations such as activated PD-1+ CD39+ T cells with potential tumor antigen specificity and increased TCR clonality found in the peripheral blood of glioma patients (90). Here, PDCD1 is linked to central nervous system cancer.